Cargando…
Environmental Designer Drugs: When Transformation May Not Eliminate Risk
[Image: see text] Environmental transformation processes, including those occurring in natural and engineered systems, do not necessarily drastically alter molecular structures of bioactive organic contaminants. While the majority of generated transformation products are likely benign, substantial c...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204896/ https://www.ncbi.nlm.nih.gov/pubmed/25216024 http://dx.doi.org/10.1021/es503425w |
_version_ | 1782340619042029568 |
---|---|
author | Cwiertny, David M. Snyder, Shane A. Schlenk, Daniel Kolodziej, Edward P. |
author_facet | Cwiertny, David M. Snyder, Shane A. Schlenk, Daniel Kolodziej, Edward P. |
author_sort | Cwiertny, David M. |
collection | PubMed |
description | [Image: see text] Environmental transformation processes, including those occurring in natural and engineered systems, do not necessarily drastically alter molecular structures of bioactive organic contaminants. While the majority of generated transformation products are likely benign, substantial conservation of structure in transformation products can imply conservation or even creation of bioactivity across multiple biological end points and thus incomplete mitigation of ecological risk. Therefore, focusing solely on parent compound removal for contaminants of higher relative risk, the most common approach to fate characterization, provides no mechanistic relationship to potential biological effects and is inadequate as a comprehensive metric for reduction of ecological risks. Here, we explore these phenomena for endocrine-active steroid hormones, focusing on examples of conserved bioactivity and related implications for fate assessment, regulatory approaches, and research opportunities. |
format | Online Article Text |
id | pubmed-4204896 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | American
Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-42048962015-09-12 Environmental Designer Drugs: When Transformation May Not Eliminate Risk Cwiertny, David M. Snyder, Shane A. Schlenk, Daniel Kolodziej, Edward P. Environ Sci Technol [Image: see text] Environmental transformation processes, including those occurring in natural and engineered systems, do not necessarily drastically alter molecular structures of bioactive organic contaminants. While the majority of generated transformation products are likely benign, substantial conservation of structure in transformation products can imply conservation or even creation of bioactivity across multiple biological end points and thus incomplete mitigation of ecological risk. Therefore, focusing solely on parent compound removal for contaminants of higher relative risk, the most common approach to fate characterization, provides no mechanistic relationship to potential biological effects and is inadequate as a comprehensive metric for reduction of ecological risks. Here, we explore these phenomena for endocrine-active steroid hormones, focusing on examples of conserved bioactivity and related implications for fate assessment, regulatory approaches, and research opportunities. American Chemical Society 2014-09-12 2014-10-21 /pmc/articles/PMC4204896/ /pubmed/25216024 http://dx.doi.org/10.1021/es503425w Text en Copyright © 2014 American Chemical Society Terms of Use (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) |
spellingShingle | Cwiertny, David M. Snyder, Shane A. Schlenk, Daniel Kolodziej, Edward P. Environmental Designer Drugs: When Transformation May Not Eliminate Risk |
title | Environmental
Designer Drugs: When Transformation
May Not Eliminate Risk |
title_full | Environmental
Designer Drugs: When Transformation
May Not Eliminate Risk |
title_fullStr | Environmental
Designer Drugs: When Transformation
May Not Eliminate Risk |
title_full_unstemmed | Environmental
Designer Drugs: When Transformation
May Not Eliminate Risk |
title_short | Environmental
Designer Drugs: When Transformation
May Not Eliminate Risk |
title_sort | environmental
designer drugs: when transformation
may not eliminate risk |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204896/ https://www.ncbi.nlm.nih.gov/pubmed/25216024 http://dx.doi.org/10.1021/es503425w |
work_keys_str_mv | AT cwiertnydavidm environmentaldesignerdrugswhentransformationmaynoteliminaterisk AT snydershanea environmentaldesignerdrugswhentransformationmaynoteliminaterisk AT schlenkdaniel environmentaldesignerdrugswhentransformationmaynoteliminaterisk AT kolodziejedwardp environmentaldesignerdrugswhentransformationmaynoteliminaterisk |